following a full submission assessed under the orphan equivalent process:
avatrombopag (Doptelet®) is accepted for restricted use within NHSScotland.
Indication under review: Treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids or immunoglobulins).
SMC restriction: to use in patients with severe symptomatic ITP or a high risk of bleeding.
In a phase III study, avatrombopag was more effective than placebo in raising and maintaining platelet counts at (or above) a minimum target level in previously-treated patients with ITP.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- avatrombopag (Doptelet)
- SMC ID:
For the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
- Pharmaceutical company
- Swedish Orphan
- BNF chapter
- Nutrition and blood
- Submission type
- Date advice published
- 09 August 2021